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Primary angiosarcoma of the breast (PAB) accounts for 0.04% of all breast malignant tumors.
It  affects young women usually at third or fourth decades of life. PAB clinically manifests as
a  painless, movable mass with sharp limits. A bluish red discoloration of the overlying skin
is  often observed. Enlargement of axillary lymph nodes generally does not occur.
Angiosarcoma of the breast has a very poor prognosis due to the tendency to metastasize
haematogenously and high frequency of local recurrence.eywords:
reast tumors
ngiosarcoma
isseminated intravascular
oagulation
Mastectomy and chemotherapy are preferable treatment choices.
This paper presents a case of primary angiosarcoma of the breast with a syndrome of
disseminated intravascular coagulation (DIC).
©  2013 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved.
observed in the lungs, skin, liver, bones, CNS, spleen, ovary,
14,15.  Background
rimary angiosarcoma of the breast (PAB) is a rare and
xtremely aggressive neoplasm of the endovascular origin.
wo hundred and nineteen cases have been documented1
ince the ﬁrst case reported by Schmidt in 1887.2 Both
chmidt and later Borrmann in 1907 described this condition
s lethal.9 The incidence rate of this tumor has remained rel-
4tively constant, accounting for 0.04% of all breast tumors.
nd approximately 8% of mammary  sarcomas.5 Several
erms have been used to describe this malignant condition
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ttp://dx.doi.org/10.1016/j.rpor.2013.10.003such as hemangioendothelioma,3 haemangioblastoma,6
hemangiosarcoma7,8 and metastasizing angioma.9–11
The usual clinical presentation of angiosarcoma is a pain-
less smooth mass, but in approximately 17% of cases the
tumor may appear with red discoloration and apparent bruis-
ing of the overlying skin.12 PAB carries very poor prognosis
with a ﬁve-year survival rate of 8–50%.13 The mean latency
ranges from 5 to 6 years. Distant metastases have beenlymph nodes and heart. The angiosarcoma may relapse
in the same breast especially after conservative surgery and
postoperative radiation.16
ed by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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Fig. 1 – A bluish red discoloration of the overlying skin of Fig. 2 – Completely surgically excised tumor.
the breast and in the middle of the abdominal region.
We  report an uncommon clinical case of an advanced
breast angiosarcoma, without distant metastases, but asso-
ciated with disseminated intravascular coagulation (DIC) by
consumption coagulopathy, known as the Kasbach–Merritt
syndrome.
2.  Case  report
The patient was a 42-year-old woman who  had a tumor in
the left breast for three years. During this period the patient
refused any treatment for her disease and no such treatment
was done. In the last two months, before the current hos-
pitalization, the tumor rapidly grew and the overlying skin
colored in red. The patient was admitted to the National Can-
cer Center Soﬁa on August 2, 2007, in a critical condition. The
physical examination revealed a hard, mobile, painless mass
located in the central region of the left breast. On palpation
the tumor dimensions were 18/16/14 cm and had sharp limits.
No enlargement of axillary lymph nodes, no nipple retraction
and no skin thickening were found. The right breast was nor-
mal. The overlying skin of the affected one had bluish red
discoloration (Fig. 1). Similar red discoloration was seen on
other parts of the body such as the back, the legs and the
middle of the abdominal region (Fig. 1). X-ray mammogra-
phy of the left breast showed a big tumor mass of 18.5 cm
in diameter, without spiculae or microcalciﬁcations. Ultra-
sound showed a liquid area in the central zone of the tumor.
The tumor marker CA15-3 was within the referenced lim-
its. Distant metastases were not established. On admission,
the coagulation tests showed exhausted haemostatic poten-
tial with low platelet count, no detectable ﬁbrinogen and
no coagulation of APTT and PT. There were high levels of
D-dimmers. These laboratory ﬁndings, together with the clin-
ically manifested bleeding diathesis with big suffusions on
the skin in the sites of venepunctures, were interpreted to be
caused by disseminated intravascular coagulation (Table 1).
D-dimers were measured using commercial antibody-based
assay.
Substitution therapy was performed with 7 units of platelet
concentrate, 10 ml/kg fresh frozen plasma and 2 units ofred blood cell concentrate. The response to the therapy was
highly satisfactory. Platelet counts reached 70 × 109/l, ﬁbrino-
gen increased to 3.5 g/l and APPT and PT were normalized.
The surgery was performed with no excessive bleeding. The
normal range of platelets was reached on the next day after
surgery with no additional substitution therapy (Table 1). The
tumor was completely excised en bloc with the ﬁrst level axil-
lary lymph nodes due to their being visibly enlarged (Fig. 2).
The mastectomy specimen showed bruising of the skin
and a well-deﬁned tumor. The cut surface of the tumor was
soft, spongy, bluish, hemangioma-like, with necroses and
hemorrhages as results of numerous dilated blood vessels
(Fig. 3).
Microscopic examination of the tumor revealed a mixed
structure – it contained areas of endothelial tufting with
papillary formation and solid spindle cell components, cor-
responding to poorly differentiated angiosarcoma – Grade 3
(Fig. 4). Hemorrhages, necroses, cellular pleomorphisms and
mitotic ﬁgures were also observed. By means of immunocito-
chemistry, endothelial marker CD 31 was used, and it strongly
stained the sarcoma cells (Fig. 5).Fig. 3 – Necrosis and hemorrhages in the central tumor
area.
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Table 1 – Coagulation status of the patients before and after therapy.
Date Platelets Fibrinogen APTT PT D-dimers
29.08.2008 28 × 109/l – 157 secunds 12% activity –
01.09.2008 50 × 109/l Not detectable No coagulation No coagulation >2000 ng/ml
02.09.2008 50 × 109/l Not detectable 51.5 secunds No coagulation –
Transfusion therapy: Fresh frozen plasma 10 ml/kg
03.09.2008 35 × 109/l 0.69 g/l 47.8 secunds 42% activity –
Transfusion therapy: Platelet concentrates 7 U; Red blood cells concentrate 2 U
04.09.2008 70 × 109/l 3.5 g/l 35.7 secunds 78% activity –
Surgery on 04.09.2008
05.09.2008 120 × 109/l – 
Fig. 4 – Primary angiosarcoma of the breast in a 42-year old
woman, HE stain, orig. magniﬁcation on ×250: areas of
endothelial tufting with papillary formation and solid
spindle cell components.
Fig. 5 – Angiosarcoma cells stained strongly for CD31,
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DIC represents the result of a widespread activation ofmmunoperoxidase labeling, orig. magniﬁcation ×250.
.  Discussion
rimary angiosarcoma of the breast is an uncommon neo-
lasm with unknown etiology. Some authors have reported
ne angiosarcoma in every 1700–2300 cases of breast
ancer.17,18– – –
Angiosarcoma occurs almost exclusively in the female
breast, with only ﬁve cases of male breast angiosarcoma being
documented.19 PAB affects primarily young women in their
thirties and forties, unlike breast carcinoma, which usually
arises later on in life.20
Breast angiosarcoma usually manifests as a palpable, pain-
less mass, moderately mobile within the surrounding tissue.
The tumor may have either ill-deﬁned or sharply circum-
scribed borders. Sometimes the disease may have a covert,
insidious clinical course, manifesting as a discrete mass that
grows rapidly, as in the case of our patient.12 Less often (in
approximately 2% of all cases), angiosarcoma may appear as
a diffusive enlargement of the breast. In most cases there is
no nipple retraction, discharge or axillary lympadenopathy.
However, a bluish red discoloration of the overlying skin is a
frequent symptom, as was also observed in this case. Tumor
size usually exceeds 4 cm in diameter.15 Here we  describe a
locally advanced tumor of 18.5 cm in diameter.
Mammography is the standard imaging approach for diag-
nostic information. Breast X-rays may appear completely
normal in about 33% of cases.21 On mammograms, angiosar-
coma appears to be a tumor mass without spiculation,
microcalciﬁcation or enlargement of the regional lymph
nodes. In our patient the mammographic ﬁndings were
nonspeciﬁc. Many other authors also reported normal mam-
mographic ﬁndings.22
Magnetic resonance imaging of angiosarcoma shows a
mass with low signal intensity on T1-weighted images. His-
tological slides demonstrate dilated channels and vascular
spaces ﬁlled with slowly ﬂowing blood.23
Preoperative diagnosis by means of aspiration cytology
and biopsy is tricky and often gives falsely negative results.
Chen et al. reported that the false negative rate was 37%.14
Therefore, immune histological staining for factor 8-related
antigens is usually beneﬁcial to the diagnosis.24
The patient’s worsening condition and probability of the
threat of bleeding prevented us from applying other diagnos-
tic tools, such as ﬁne needle biopsy and magnetic resonance.
In patients with cancer, the pathogenic mechanism of hema-
tologic disorders such as DIC is not clearly understood. From
the clinical viewpoint, most cases of cancer-associated hema-
tologic disorders have been reported in patients with gastric
and breast cancer.24–26the coagulation pathway.27 DIC proceeds from the simulta-
neous occurrence of systemic ﬁbrin formation resulting from
an increased generation of thrombi, impaired physiological
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anticoagulation mechanism, and inadequate ﬁbrinolysis. The
combination of increased formation and impaired removal of
ﬁbrin results in thrombotic occlusion of small and medium
sized vessels. In cancer patients, tumor cells express a vari-
ety of procoagulant molecules including tissue factor and
cancer procoagulant, which activate the host’s hemostatic
system.28,29 Tumor cells also express ﬁbrinolytic inhibitors
such as plasminogen activator type 1, creating the hypoﬁb-
rinolytic state that is characteristic of DIC.30 Proinﬂammatory
cytokines, such as tumor necrosis factor  and interleukin-6,
are also involved in DIC development.31,32
Kasabach–Merritt syndrome (KMS) is deﬁned by a huge
haemangioma with thrombocytopenia and consumption
coagulopathy.33 Endothelial defects within the haemangioma
cause platelet activation, thrombosis formation, consumption
of coagulation factors, and increased ﬁbrinolysis because of
localized intravascular coagulation.34 Studies using radiola-
beled ﬁbrinogen and platelets have provided evidence that
within the hemangioma, tere occurs the consumption of
platelets and ﬁbrinogen.35 Kasabach–Merritt syndrome was
originally described in benign haemangioma. We  observed the
same process in a malignant tumor of endothelial origin and
cavernous space in it. Since the rate of consumption of the
coagulation potential was of a low grade, it was corrected with
limited amount of platelets and fresh frozen plasma.
Concerning the possible mechanism of the coagulation dis-
order two  possibilities may be discussed:
1. Despite the malignant origin of the tumor, the activation
of coagulation was most probably only local and did not
engage the complex mechanisms of DIC associated with
malignancy.
2. There was a combination of these two possible mecha-
nisms in a low grade.
Due to the unknown etiological factors of this rare
malignancy, there is no established standard treatment.
Mastectomy is treatment of choice, in some cases breast con-
serving surgery may also be considered. Complete surgical
excision is found to be better than what is generally believed.
Adjuvant chemotherapy is often carried out on patients with
primary breast angiosarcoma and distant metastases, but the
results are unsatisfactory.12,15,36
Recently, a new treatment approach has been investigated.
Endoglin is an antigen that is found mainly on the surface
of endothelial cells.37 Thorpe et al. suggested that it may be
possible to treat angiosarcoma with anti-endoglin monoclonal
antibodies if immunohistochemical staining is positive for
endoglin.38 Their assumptions are based on the close inter-
action between endothelial cells and the blood. This makes
vasculature a practical target for therapy.
Prognosis of angiosarcoma is thought to depend on the
histological grade.39 Patients with higher grade lesions are
more  prone to higher rates of local recurrences and have
a lower survival rate.18,21 In our patient the tumor was
found to be of a relatively high grade, and subsequently she
was referred to adjuvant therapy. Poor prognosis of breast
angiosarcoma is associated also with a tendency to metas-
tasize hematogenously.23
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